Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: US FDA’s ‘Within Label’ Definition Allows Companies To Elaborate On Indications

Executive Summary

Permitted speech for approved products could shift dramatically depending on how hard a Trump FDA Commissioner pushes, but the expansion at the end of the Obama Administration is a significant step in its own right – one that former Commissioner Rob Califf emphasizes in an interview that is also available as a podcast.

Advertisement

Related Content

FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Off-Label Communication: When Does It Align With Approved Labeling?

Topics

Advertisement
UsernamePublicRestriction

Register

PS119983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel